Stock Performance and Market Reaction - Moderna shares surged 12% to 4753onTuesdaydrivenbyinvestoroptimismaroundthecompany′sdevelopmentofanH5N1birdfluvaccinefollowingthefirstreporteddeathlinkedtothediseaseintheUS[2][10]−Thestockhasshownastrongstarttotheyearafterlosingmorethanhalfofitsvaluein2024duetodecliningdemandforitsCovid−19products[3]−Thestockcloseddecisivelyabovethe50−daymovingaverageonthehighesttradingvolumesinceDecember′striplewitchingsessionindicatingbullishmomentum[4][10]TechnicalAnalysisandKeyPriceLevels−Therelativestrengthindex(RSI)confirmsbullishmomentumwithareadingabove65butremainsbelowoverboughtlevelssuggestingroomforfurtherpriceappreciation[4]−Keyoverheadresistancelevelstowatchinclude57 near the upper level of a consolidation period from October to November 2023 72neartheearly−Septemberlowandsubsequentcountertrendpeakand85 near a multi-month horizontal line connecting the February low with August price points [6][7] - Important support levels to monitor include 44wherethe50−dayMAandashort−termtrendlineconvergeand37 near the November swing low which could present buying opportunities during pullbacks [8] Strategic Considerations for Investors - Investors who purchased the stock at lower levels may consider offloading shares around the 85levelduetopotentialresistancefromthefalling200−dayMA[7]−Acloseabovethe57 resistance level could signal further upward momentum potentially driving the stock toward the 72and85 levels [6][7] - A breakdown below the 44supportlevelcouldleadtoaretestofthe37 level offering potential entry points for new investors [8]